BNGO logo

BIONANO GENOMICS INC

BNGONASDAQ
๐Ÿ† #4214 by market capEarnings Oct 29US Equity
$1.17โ–ผ $0.02 (โˆ’1.67%)
Live
1hโ–ผ 0.4%
24hโ–ผ 1.7%
7dโ–ฒ 8.8%
14dโ–ฒ 7.8%
30dโ–ฒ 0.0%
1yโ–ผ 61.6%
๐ŸฆMarket Cap
$13M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+1.0%
Slowing
๐Ÿ“ŠGross Margin
47.0%
Healthy
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
0.5x
Cheap
Otter Score
58
Weak

Trading Snapshot

Day Range
$1.15 โ€“ $1.19
52-Week Range
$1.00 โ€“ $5.50
Volume
$2.01B
Avg Volume
$2.10B
Shares Outstanding
11.5M
Next Earnings
Sep 7, 2026

Fundamentals Snapshot

Annual Revenue
$29M
Last Q Revenue
$8M
P/E Ratio
โ€”
P/S Ratio
0.5x
EPS (TTM)
$-5.11
Dividend Yield
โ€”

Why Investors Own BNGO

  • โœ“High-growth profile โ€” revenue up +47.1% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 61% gross margin and 11% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$29Mโ–ฒ +53.6% YoY
Gross Margin (TTM)
60.6%โ–ผ โˆ’0.2% YoY
Operating Income (TTM)
$8Mโ–ฒ +53.6% YoY
Free Cash Flow (TTM)
$3Mโ–ฒ +53.6% YoY

About BIONANO GENOMICS INC

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
58/100

Analyst Ratings

โ“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates